Stanley Stringam, MD
Internal Medicine · Nampa, IDNPI 1902896913
Payments from drug & device makers
Across 916 payments — averaging $503.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$157K
- Novo Nordisk AS$136K
- Eli Lilly$116K
- Sanofi US Services Inc.$27K
- Merck$15K
- Pfizer$9K
- plus $2K from 23 others
Across 10 payments — averaging $382.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2K
- Novo Nordisk AS$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 19 | $156,979 |
| Novo Nordisk AS | 731 | $136,270 |
| Eli Lilly | 13 | $115,641 |
| Sanofi US Services Inc. | 4 | $27,153 |
| Merck | 6 | $14,591 |
| Pfizer | 36 | $8,580 |
| Novo Nordisk | 23 | $349 |
| Boehringer Ingelheim | 10 | $157 |
| Amgen | 9 | $146 |
| Johnson & Johnson | 10 | $141 |
| AstraZeneca | 9 | $130 |
| E.r. Squibb & Sons, L.L.C. | 9 | $123 |
| Dexcom, Inc. | 4 | $91 |
| AbbVie(2 entities) | 5 | $78 |
| GSK | 4 | $64 |
| Astellas Pharma US Inc | 4 | $56 |
| Sanofi-aventis U.S. LLC | 3 | $38 |
| Abbott | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 3 | $35 |
| Corcept Therapeutics | 2 | $31 |
| Exact Sciences | 2 | $31 |
| Lucid Diagnostics Inc. | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Gilead | 1 | $16 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Medtronic | 1 | $12 |
| Sunovion Pharmaceuticals Inc. | 1 | $11 |
How this compares
$460,843 in reported general payments places this provider in the 95th percentile of 289 internal medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Nampa
- Sarah BarkerNampa$5K
- John SadajNampa$5K
- Michael DeeNampa$2K
- Ryan WilliamsNampa$492
- Marian ShawBoise$7.8M
- Hira SiktelChubbuck$4.5M
- Kevin PrierIdaho Falls$2.9M
- Gary UlleryBlackfoot$1.7M
- Sherwin D'souzaPocatello$945K
- Tarek BarbarChubbuck$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.